Pfizer has abandoned work on a PD-L1-targeting drug that was being tested in patients with various cancers. | Pfizer has ...

The GLP-1 agonist at the center of Pfizer’s upfront $4.9 billion buyout of Metsera last week has been tied to 14.1% weight loss at 28 weeks as well as “potentially class-leading tolerability,” ...

A change to FDA clinical trial data review, Rocket sells its priority review voucher, and more biotech news from The Readout ...

The pharmaceutical company has been investing in its future growth, but whether its efforts will pay off is a big question ...

Pfizer, by contrast, appears diversified but diffuse—its pipeline may contain value, but that value is not yet organized into ...

Novo Nordisk and Pfizer's multibillion-dollar fight over who gets to buy an anti-obesity biotech has morphed into a narrative argument over which acquisition would be most America First — a framing ...

COPENHAGEN (Reuters) -Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer as drugmakers jostle for advantage in the ...

Andrew Baum, a former Citi analyst, has left his role as Pfizer's executive vice president and chief strategy and innovation ...

Pfizer's vaccine business cooled off, and it is on its back foot in the GLP-1 race, but don't count the drug giant out.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Pfizer-backed biotech landed ...

Pfizer has a higher-yielding dividend, but it may not be safe. AbbVie has the better path to growth in 2026. But when you ...

During Pfizer's right-sizing push after the COVID-19 pandemic, the company's multibillion-dollar cost-cutting campaign has ...